4D Pharma PLC Warrant
LBPSW
LBPSW was delisted on the 29th of June, 2022.
5 hedge funds and large institutions have $2.81M invested in 4D Pharma PLC Warrant in 2021 Q4 according to their latest regulatory filings, with 1 funds opening new positions, increasing their positions, 1 reducing their positions, and 2 closing their positions.
794% more capital invested
Capital invested by funds: $315K → $2.81M (+$2.5M)
17% less funds holding
Funds holding: 6 → 5 (-1)
50% less first-time investments, than exits
New positions opened: 1 | Existing positions closed: 2
100% less repeat investments, than reductions
Existing positions increased: 0 | Existing positions reduced: 1
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
UBS Group
Zurich,
Switzerland
|
+$915 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AA
AQR Arbitrage
Greenwich,
Connecticut
|
-$28.9K |
| 2 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$8K |
| 3 |
HIM
HGC Investment Management
Toronto,
Ontario, Canada
|
-$4K |
LBPSW Hedge Fund Activity: Q4 2021 in Review
5 of the 6,498 institutional investors tracked by Wall St. Rank reported a position in 4D Pharma PLC Warrant (LBPSW) for Q4 2021, worth a combined $2.81M — up 794% from $315K a quarter earlier.
Sellers outnumbered buyers: 2 funds closed out of LBPSW and 1 opened new positions — a net loss of 1 holder — while 1 trimmed existing stakes and 0 added.
The largest buyer was UBS Group, opening a new position worth an estimated $915. The largest seller was AQR Arbitrage, cutting an estimated $28.9K.
- 5 institutional investors held 4D Pharma PLC Warrant (LBPSW) as of Q4 2021, down from 6 in Q3 2021.
- Funds reported $2.81M of 4D Pharma PLC Warrant stock for Q4 2021, up 794% quarter-over-quarter.
- 1 fund opened new 4D Pharma PLC Warrant positions in Q4 2021 and 2 closed out, a net change of -1 holder.
- The largest 4D Pharma PLC Warrant buyer in Q4 2021 was UBS Group, an estimated $915 added.
- The largest 4D Pharma PLC Warrant seller in Q4 2021 was AQR Arbitrage, an estimated $28.9K sold.
Based on aggregated 13F filings for Q4 2021.